Matthew Henn

Motivated medical student with diverse experience in business and leadership

Matthew Henn is a prominent figure in the biotechnology sector, currently serving on the Board of Advisors at Life Sciences Cares since November 2021. He is also the Executive Vice President and Chief Scientific Officer at Seres Therapeutics, a role he has held since January 2019. In this position, he focuses on developing microbiome therapeutics aimed at treating infectious and inflammatory diseases, leveraging a robust pipeline of clinical assets.1

Professional Background

Seres Therapeutics: Henn has held various leadership roles within the company since 2012, including Senior VP of Drug Discovery and Bioinformatics.
Broad Institute: Before joining Seres, he worked at the Broad Institute in multiple capacities, including Director of Viral Genomics.
Academic Credentials: He holds a Ph.D. from the University of California, Berkeley, and a B.S. from the University of New Hampshire. Henn was also a postdoctoral fellow at Duke University and UC Berkeley.1 2

Contributions and Impact

Henn's work primarily revolves around microbiome research, where he aims to innovate therapeutic approaches that address complex health issues. His expertise has positioned him as a key player in advancing microbiome science within the pharmaceutical landscape.2 3

Highlights

Aug 30 · fda.gov

[PDF] 26. Session 2I Matt Henn - FDA

Experience

Medical Student at Oregon Health & Science University (July 2022 - Present)

Account Executive at NAVEX (June 2021 - July 2022)

Education

Doctor of Medicine - MD in Medicine from Oregon Health & Science University (2022 - 2026), Bachelor of Science - BS in Business Administration with an Emphasis in Business Intelligence from Grand Canyon University (2012 - 2017), Graduated Summa Cum Laude